A few summers ago, Andrea lost a flip-flop. Anyone can misplace a shoe. But this was the only thing between Andrea’s foot and the London pavement. She didn’t notice that it was gone. She began dropping things then, too. “I couldn’t feel the pressure that I was applying when I was holding drinks. Quite often, they would just slip through my hands.” As they smashed and shattered on the floor, glasses didn’t feel like the only things Andrea was struggling to keep hold of. She was a young mother with bowel cancer, grappling with her mortality while trying to do her daughter’s hair. And these symp ..read more

A study published in the Journal of Clinical Oncology has found that the level of a person’s immune cells may provide an indication of whether they would benefit from chemotherapy in a type of cancer called oropharyngeal squamous cell carcinoma (OPSCC). These cells, called lymphocytes, are a type of white blood cell that form an essential part of the immune system. The current standard of care for OPSCC involves radiotherapy and chemotherapy. However, the use of cisplatin chemotherapy increases the amount and severity of side effects, compared to radiotherapy alone. To avoid the potential sid ..read more

Cannabis, cannabinoids and cancer – the evidence so far The post Can we grow the treatments of tomorrow? – That Cancer Conversation first appeared on Cancer Research UK - Cancer news ..read more

The National Institute for Health and Care Excellence (NICE) has recommended a new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma on the NHS in England. After an initial rejection back in March, a combination of polatuzumab vedotin (Polivy) and 2 existing cancer drugs – rituximab and bendamustine – will now be available to some adults with diffuse large B cell lymphoma. It will be a new option for people whose cancer has either not responded to, or come back after, initial treatment, and who are unable to have a stem cell transplant. NICE decisions are usually ..read more

Combining an immunotherapy drug, which stimulates the immune system to target lung cancer cells, with chemotherapy has been recommended as a treatment for some patients with lung cancer on the NHS in England. Cancer Research UK says the decision to approve the pembrolizumab (Keytruda) combination for some adults with a type of untreated non small cell lung cancer is a “welcome step forward”. The treatment combo, which has been shown to improve survival in patients with squamous non small cell lung cancer that has spread to other part of the body, will now be available on the Cancer Drugs Fund ..read more